Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 11, 2003, Pages 3464-3469

  Park, Ji Young ^a   Kim, Kyoung Ah ^a   Kim, Su Lyun ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; COMPLEMENTARY DNA; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; MIDAZOLAM; PHENYTOIN;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME MECHANISM; GENE EXPRESSION; HUMAN; LIVER MICROSOME; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHLORAMPHENICOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PHENYTOIN;

EID: 0242290979     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.11.3464-3469.2003     Document Type: Article

References (42)

1. Abdel-Rahman, S. M., K. Marcucci, T. Boge, R. R. Gotschall, G. L. Kearns, and J. S. Leeder. 1999. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab. Dispos. 27:770-775.
2. Adams, H. R., E. L. Isaacson, and B. S. Masters. 1977. Inhibition of hepatic microsomal enzymes by chloramphenicol. J. Pharmacol. Exp. Ther. 203:388-396.
3. Bajpai, M., L. K. Roskos, D. D. Shen, and R. H. Levy. 1996. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 24:1401-1403.
4. Bui, L., and D. D. Huang. 1999. Possible interaction between cyclosporine and chloramphenicol. Ann. Pharmacother. 33:252-253.
5. Desta, Z., X. Zhao, J. G. Shin, and D. A. Flockhart. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913-958.
6. Donahue, S., D. A. Flockhart, and D. R. Abernethy. 1999. Ticlopidine inhibits phenytoin clearance. Clin. Pharmacol. Ther. 66:563-568.
7. Giancarlo, G. M., K. Venkatakrishnan, B. W. Granda, L. L. von Moltke, and D. J. Greenblatt. 2001. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol. 57:31-36.
8. Halpert, J., B. Naslund, and I. Betner. 1983. Suicide inactivation of rat liver cytochrome P-450 by chloramphenicol in vivo and in vitro. Mol. Pharmacol. 23:445-452.
9. Holt, D., D. Harvey, and R. Hurley. 1993. Chloramphenicol toxicity. Adverse Drug React. Toxicol. Rev. 12:83-95.
10. Houghton, G. W., and A. Richens. 1975. Inhibition of phenytoin metabolism by other drugs used in epilepsy. Int. J. Clin. Pharmacol. Biopharm. 12:210-216.
11. Kaminsky, L. S., and Z. Y. Zhang. 1997. Human P450 metabolism of warfarin. Pharmacol. Ther. 73:67-74.
12. Knoell, K. R., T. M. Young, and E. S. Cousins. 1998. Potential interaction involving warfarin and ritonavir. Ann. Pharmacother. 32:1299-1302.
13. Ko, J. W., Z. Desta, N. V. Soukhova, T. Tracy, and D. A. Flockhart. 2000. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br. J. Clin. Pharmacol. 49:343-351.
14. Koup, J. R., M. Gibaldi, P. McNamara, D. M. Hilligoss, W. A. Colburn, and E. Bruck. 1978. Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin. Pharmacol. Ther. 24:571-575.
15. Kraner, J. C., E. T. Morgan, and J. R. Halpert. 1994. Selective suppression of rat hepatic cytochrome P450 2C11 by chloramphenicol. J. Pharmacol. Exp. Ther. 270:1367-1372.
16. Kronbach, T., V. Fischer, and U. A. Meyer. 1988. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:630-635.
17. Leone, R., E. Ghiotto, A. Conforti, and G. Velo. 1999. Potential interaction between warfarin and ocular chloramphenicol. Ann. Pharmacother. 33:114.
18. Levy, R. H. 1995. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 36:S8-S13.
19. Lucas, D., J. F. Menez, and F. Berthou. 1996. Chlorzoxazone: an in vitro and in vivo substrate probe for liver CYP2E1. Methods Enzymol. 272:115-123.
20. Mathis, A. S., N. Shah, G. T. Knipp, and G. S. Friedman. 2002. Interaction of chloramphenicol and the calcineurin inhibitors in renal transplant recipients. Transplant. Infect. Dis. 4:169-174.
21. Miners, J. O., and D. J. Birkett. 1998. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45: 525-538.
22. Papanicolaou, G. A., B. R. Meyers, J. Meyers, M. H. Mendelson, W. Lou, S. Emre, P. Sheiner, and C. Miller. 1996. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin. Infect. Dis. 23:760-766.
23. Perloff, M. D., L. L. von Moltke, M. H. Court, T. Kotegawa, R. I. Shader, and D. J. Greenblatt. 2000. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J. Pharmacol. Exp. Ther. 292:618-628.
24. Porter, T. D., and M. J. Coon. 1991. Cytochrome P450. Multiplicity of isoforms, substrates, and catalytic regulatory mechanisms. J. Biol. Chem. 266:13469-13472.
25. Powell, D. A., M. C. Nahata, D. C. Durrell, J. P. Glazer, and M. D. Hilty. 1981. Interactions among chloramphenicol, phenytoin, and phenobarbital in a pediatric patient. J. Pediatr. 98:1001-1003.
26. Rendic, S., and F. J. Di Carlo. 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29:413-580.
27. 14C]phenacetin O-deethylase activity in human liver microsomes. Drug Metab. Dispos. 25:1097-1100.
28. Rodrigues, A. D. 1999. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol. 57:465-480.
29. Rose, J. Q., H. K. Choi, J. J. Schentag, W. R. Kinkel, and W. J. Jusko. 1977. Intoxication caused by interaction of chloramphenicol and phenytoin. JAMA 237:2630-2631.
30. Sastry, V., P. J. Brennan, M. M. Levy, N. Fishman, A. L. Friedman, A. Naji, C. F. Barker, and K. L. Brayman. 1995. Vancomycin-resistant enterococci: an emerging pathogen in immunosuppressed transplant recipients. Transplant. Proc. 27:954-955.
31. Sattler, M., F. P. Guengerich, C. H. Yun, U. Christians, and K. F. Sewing. 1992. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20:753-761.
32. Schulman, S. L., L. M. Shaw, K. Jabs, M. B. Leonard, and K. L. Brayman. 1998. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation 65:1397-1398.
33. Schwartz, J., K. Bachmann, and E. Perrigo. 1983. Interaction between warfarin and erythromycin. South. Med. J. 76:91-93.
34. Shimada, T., H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423.
35. Shin, J. G., J. Y. Park, M. J. Kim, J. H. Shon, Y. R. Yoon, I. J. Cha, S. S. Lee, S. W. Oh, S. W. Kim, and D. A. Flockhart. 2002. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab. Dispos. 30:1102-1107.
36. Taber, D. J., R. E. Dupuis, K. D. Hollar, A. L. Strzalka, and M. W. Johnson. 2000. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. Transplant. Proc. 32:660-662.
37. Villeneuve, J. P., L. L'Ecuyer, S. De Maeght, and P. Bannon. 2000. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. Clin. Pharmacol. Ther. 67:242-248.
38. Vincent, F. M., L. Mills, and J. K. Sullivan. 1978. Chloramphenicol-induced phenytoin intoxication. Ann. Neurol. 3:469.
39. von Moltke, L. L., D. J. Greenblatt, J. Schmider, C. E. Wright, J. S. Harmatz, and R. I. Shader. 1998. In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 55:113-122.
40. Walle, T. 1996. Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro. Methods Enzymol. 272:145-151.
41. Yamazaki, H., and T. Shimada. 1997. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem. Pharmacol. 54:1195-1203.
42. Yeh, J., S. C. Soo, C. Summerton, and C. Richardson. 1990. Potentiation of action of warfarin by itraconazole. Br. Med. J. 301:669.